SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 3,738 shares of SiBone stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $22.50, for a total transaction of $84,105.00. Following the completion of the sale, the insider directly owned 214,497 shares in the company, valued at approximately $4,826,182.50. The trade was a 1.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Anshul Maheshwari also recently made the following trade(s):
- On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total transaction of $33,754.50.
- On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total value of $60,321.24.
- On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96.
- On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $224,784.56.
- On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total transaction of $112,353.85.
- On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total value of $87,002.25.
SiBone Price Performance
Shares of NASDAQ:SIBN opened at $24.95 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 7.55 and a current ratio of 9.15. The business’s fifty day moving average price is $19.61 and its two-hundred day moving average price is $16.52. The stock has a market cap of $1.11 billion, a PE ratio of -80.48 and a beta of 0.64. SiBone has a one year low of $11.48 and a one year high of $25.92.
SiBone (NASDAQ:SIBN – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.62%. The firm had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. On average, analysts forecast that SiBone will post -0.40 EPS for the current fiscal year.
Institutional Trading of SiBone
A number of institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc grew its position in SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after buying an additional 887 shares in the last quarter. D.A. Davidson & CO. increased its holdings in shares of SiBone by 2.8% in the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock valued at $711,000 after purchasing an additional 1,038 shares in the last quarter. State of Wyoming grew its position in shares of SiBone by 70.8% during the 1st quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after buying an additional 4,490 shares during the period. Quantinno Capital Management LP increased its holdings in SiBone by 58.2% in the first quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock valued at $372,000 after purchasing an additional 10,848 shares during the last quarter. Finally, Inceptionr LLC acquired a new stake in SiBone in the first quarter worth $156,000. 98.11% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about SiBone
Here are the key news stories impacting SiBone this week:
- Positive Sentiment: Q3 results topped estimates. SiBone reported a loss of $0.08 per share, narrower than analysts’ expected $0.13 loss, and revenue of $55.7 million versus $55.3 million expected. Q3 earnings report
- Positive Sentiment: Analysts raised price targets and maintained Buy ratings. UBS lifted its target to $26 from $25, while TD Cowen raised its target to $23 from $20. These revisions indicate continued analyst support, although TD Cowen’s target is below the recent share price. UBS ratings TD Cowen ratings
- Neutral Sentiment: 2026 revenue guidance was reaffirmed. SiBone forecast full-year revenue of $231 million to $233 million, broadly in line with the $232.2 million consensus estimate, providing little change to expectations. Company Q3 results and guidance
- Negative Sentiment: Two insiders sold shares. Director Jeffrey W. Dunn sold 20,000 shares, cutting his stake by 55.47%; insider Anshul Maheshwari sold 3,738 shares. Insider selling can weigh on sentiment, though both retained shares after their transactions. Dunn SEC filing Maheshwari transaction details
Analyst Ratings Changes
A number of research analysts have weighed in on SIBN shares. Truist Financial increased their price target on SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. Needham & Company LLC lowered their price objective on SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday. TD Cowen upped their target price on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday. UBS Group increased their target price on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Citigroup reissued a “market outperform” rating on shares of SiBone in a research note on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, SiBone has an average rating of “Moderate Buy” and an average price target of $25.00.
Read Our Latest Stock Report on SiBone
SiBone Company Profile
SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.
Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.
Featured Articles
- Five stocks we like better than SiBone
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
